Submit Article

All Categories

Learn Economics

About Us

Authors

Apply

Sign Up

Latest

Markets

Policy & Regulation

Opinion

Business & Deals

Future Outlook

History Parallels

Submit Article

Learn Economics

About Us

Authors

Apply

Sign Up

Latest

Markets

Opinion

Business & Deals

Future Outlook

All Categories

Jack Breaks
Staff Writer, The Fershman Journal
Jack is a first-year at the University of Chicago planning to major in Business Economics and Biology. He is interested in the economics of human health — specifically how shocks in biology (e.g. GLP-1 drugs) rewrite market structure, consumer demand, food systems, and corporate strategy. For Fershman, he is especially interested in writing about the future of obesity drugs, the incentives in the healthcare system, and how investors value treatments that depend on behavior change versus treatments that work at the molecular level.
Jack Breaks
Staff Writer, The Fershman Journal
Jack is a first-year at the University of Chicago planning to major in Business Economics and Biology. He is interested in the economics of human health — specifically how shocks in biology (e.g. GLP-1 drugs) rewrite market structure, consumer demand, food systems, and corporate strategy. For Fershman, he is especially interested in writing about the future of obesity drugs, the incentives in the healthcare system, and how investors value treatments that depend on behavior change versus treatments that work at the molecular level.
Jack Breaks
Staff Writer, The Fershman Journal
Jack is a first-year at the University of Chicago planning to major in Business Economics and Biology. He is interested in the economics of human health — specifically how shocks in biology (e.g. GLP-1 drugs) rewrite market structure, consumer demand, food systems, and corporate strategy. For Fershman, he is especially interested in writing about the future of obesity drugs, the incentives in the healthcare system, and how investors value treatments that depend on behavior change versus treatments that work at the molecular level.

Jack Breaks — Articles

Jack Breaks — Articles

Jack Breaks — Articles

Pfizer’s $5 Billion GLP-1 Bet Looks Like a Catch-Up Trade
Author Image

Jack Breaks

Feb 6, 2026

Pfizer’s acquisition of Metsera comes at a steep price: nearly three times the company’s valuation just eight months earlier. After abandoning its own GLP-1 program, Pfizer is paying a large premium to reenter the obesity market late. But the deal raises a question of whether Pfizer already lost?

Pfizer’s $5 Billion GLP-1 Bet Looks Like a Catch-Up Trade
Author Image

Jack Breaks

Feb 6, 2026

Pfizer’s acquisition of Metsera comes at a steep price: nearly three times the company’s valuation just eight months earlier. After abandoning its own GLP-1 program, Pfizer is paying a large premium to reenter the obesity market late. But the deal raises a question of whether Pfizer already lost?

Pfizer’s $5 Billion GLP-1 Bet Looks Like a Catch-Up Trade

Feb 6, 2026

Pages

Authors

Categories

Links

Subscribe

Contact

Privacy Policy

© 2025 Fershman

Pages

Authors

Categories

Links

Subscribe

Contact

Privacy Policy

© 2025 Fershman

Pages

Authors

Categories

Links

Subscribe

Contact

Privacy Policy